References
- Hu C, Zhang Y, Bi X, et al. Correlation between serum trimethylamine-N-oxide concentration and protein energy wasting in patients on maintenance hemodialysis. Ren Fail. 2022;44(1):1669–1676.
- Stubbs JR, House JA, Ocque AJ, et al. Serum trimethylamine N-oxide is elevated in CKD and correlates with coronary atherosclerosis burden. J Am Soc Nephrol. 2016;27(1):305–313.
- Hai X, Landeras V, Dobre MA, et al. Mechanism of prominent trimethylamine oxide (TMAO) accumulation in hemodialysis patients. PLOS One. 2015;10(12):e0143731.
- Pelletier CC, Croyal M, Ene L, et al. Elevation of trimethylamine-N-oxide in chronic kidney disease: contribution of decreased glomerular filtration rate. Toxins. 2019;11(11):635.
- Dai L, Meijers BK, Bammens B, et al. Sevelamer use in end-stage kidney disease (ESKD) patients associates with poor vitamin K status and high levels of gut-derived uremic toxins: a drug–bug interaction? Toxins. 2020;12(6):351.
- Lin TY, Hung SC. Association of subjective global assessment of nutritional status with gut microbiota in hemodialysis patients: a case-control study. Nephrol Dial Transplant. 2021;36(6):1104–1111.
- Kalagi NA, Abbott KA, Alburikan KA, et al. Modulation of circulating trimethylamine N-oxide concentrations by dietary supplements and pharmacological agents: a systematic review. Adv Nutr. 2019;10(5):876–887.
- Missailidis C, Hallqvist J, Qureshi AR, et al. Serum trimethylamine-N-oxide is strongly related to renal function and predicts outcome in chronic kidney disease. PLOS One. 2016;11(1):e0141738.
- Sabatino A, Regolisti G, Karupaiah T, et al. Protein-energy wasting and nutritional supplementation in patients with end-stage renal disease on hemodialysis. Clin Nutr. 2017;36(3):663–671.